Preferred Label : durvalumab;
Obsolete resource : false;
MeSH hyponym : MEDI-4736;
UNII : 28X28X9OKV;
Origin ID : C000613593;
UMLS CUI : C4055109;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://ansm.sante.fr/tableau-acces-derogatoire/imfinzi-50-mg-ml-solution-a-diluer-pour-perfusion
2025
false
false
false
France
French
summary of product characteristics
package leaflet
durvalumab
guidelines for drug use
Unresectable Biliary Tract Carcinoma
antineoplastic combined chemotherapy protocols
Metastatic Biliary Tract Carcinoma
durvalumab
adult
Cisplatin/Durvalumab/Gemcitabine Regimen
infusions, intravenous
cisplatin
carcinoma, hepatocellular
carcinoma, non-small-cell lung
small cell lung carcinoma
bronchial neoplasms
---
https://www.has-sante.fr/jcms/p_3590639/fr/imfinzi-lynparza-durvalumab/olaparib-cancer-de-l-endometre
2025
false
false
false
France
antineoplastic combined chemotherapy protocols
insurance, health, reimbursement
treatment outcome
Antineoplastic Agents, Immunological
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
Mismatch Repair Proficient
Mismatch Repair Deficiency
durvalumab
durvalumab
olaparib
olaparib
evaluation of the transparency committee
endometrial neoplasms
---
https://www.has-sante.fr/jcms/p_3576306/fr/imfinzi-durvalumab-et-lynparza-olaparib-en-association-cancer-de-l-endometre
2025
false
false
false
France
evaluation of the transparency committee
olaparib
cancer
Imfinzi
endometrial neoplasms
durvalumab
Lynparza
endometrium
neoplasm, malignant
olaparib
association
olaparib
durvalumab
Endomet
---
https://www.has-sante.fr/jcms/p_3590636/fr/imfinzi-durvalumab-cancer-de-l-endometre
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
durvalumab
antineoplastic combined chemotherapy protocols
Mismatch Repair Deficiency
adult
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
neoplasm recurrence, local
infusions, intravenous
evaluation of the transparency committee
durvalumab
endometrial neoplasms
---
https://www.has-sante.fr/jcms/p_3468175/fr/imfinzi-durvalumab-cancer-des-voies-biliaires
2024
false
false
false
France
Cisplatin/Durvalumab/Gemcitabine Regimen
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
cisplatin
Gemcitabine
Unresectable Biliary Tract Carcinoma
Metastatic Biliary Tract Carcinoma
neoplasm metastasis
Antineoplastic Agents, Immunological
durvalumab
adult
guidelines for drug use
evaluation of the transparency committee
biliary tract cancer
biliary tract neoplasms
durvalumab
---
https://ansm.sante.fr/actualites/decision-du-06-05-2024-renouvellement-du-cpc-du-medicament-imfinzi-durvalumab-50-mg-ml-solution-a-diluer-pour-perfusion
2024
false
false
false
France
French
drug information
durvalumab
---
https://www.has-sante.fr/jcms/p_3519904/fr/imfinzi-durvalumab-et-lynparza-olaparib-en-association-cancer-de-l-endometre
2024
false
false
false
France
antineoplastic combined chemotherapy protocols
endometrial neoplasms
evaluation of the transparency committee
durvalumab
olaparib
---
https://www.has-sante.fr/jcms/p_3555565/fr/imfinzi-durvalumab-carcinome-hepatocellulaire-chc
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
durvalumab
evaluation of the transparency committee
carcinoma, hepatocellular
durvalumab
---
https://www.has-sante.fr/jcms/p_3506840/fr/imfinzi-durvalumab-cancer-bronchique-non-a-petites-cellules
2024
false
false
false
France
evaluation of the transparency committee
Imfinzi
Durvalumab
durvalumab
durvalumab
---
https://www.has-sante.fr/jcms/p_3459834/fr/imfinzi-/-tremelimumab-astrazeneca-durvalumab-/-tremelimumab-cancer-bronchique-non-a-petites-cellules-cbnpc
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
platinum compounds
antineoplastic combined chemotherapy protocols
Antineoplastic Agents, Immunological
bronchial neoplasms
neoplasm metastasis
Metastatic Lung Non-Small Cell Carcinoma
Activating EGFR Gene Mutation Negative
Activating ALK Gene Mutation Negative
Durvalumab/Tremelimumab Regimen
evaluation of the transparency committee
tremelimumab
carcinoma, non-small-cell lung
durvalumab
---
https://www.has-sante.fr/jcms/p_3448228/fr/imjudo-/-imfinzi-tremelimumab-/-durvalumab-carcinome-hepato-cellulaire-chc
2023
false
false
false
France
antineoplastic combined chemotherapy protocols
Durvalumab/Tremelimumab Regimen
insurance, health, reimbursement
treatment outcome
infusions, intravenous
adult
Advanced Adult Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma
Child-Pugh Class A
ECOG Performance Status 0
ECOG Performance Status 1
evaluation of the transparency committee
carcinoma, hepatocellular
durvalumab
tremelimumab
---
https://www.has-sante.fr/jcms/p_3418037/fr/imfinzi-durvalumab-carcinome-hepato-cellulaire
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
tremelimumab
durvalumab
adult
Advanced Adult Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma
Child-Pugh Class A
ECOG Performance Status 0
ECOG Performance Status 1
infusions, intravenous
evaluation of the transparency committee
durvalumab
carcinoma, hepatocellular
---
https://www.has-sante.fr/jcms/p_3451406/fr/imfinzi-durvalumab-cancer-des-voies-biliaires-cvb
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
Cisplatin/Durvalumab/Gemcitabine Regimen
durvalumab
Metastatic Biliary Tract Carcinoma
biliary tract neoplasms
Unresectable Biliary Tract Carcinoma
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
Antineoplastic Agents, Immunological
durvalumab
---
https://www.has-sante.fr/jcms/p_3372376/fr/imfinzi-durvalumab-cancer-des-voies-biliaires
2022
false
false
false
France
durvalumab
durvalumab
Cisplatin/Durvalumab/Gemcitabine Regimen
antineoplastic combined chemotherapy protocols
cisplatin
antineoplastic agents
guidelines for drug use
infusions, intravenous
adult
biliary tract cancer
Unresectable Biliary Tract Carcinoma
Metastatic Biliary Tract Carcinoma
Gemcitabine
evaluation of the transparency committee
---
https://pgtmsite.files.wordpress.com/2024/01/re_durvalumab_strategie-posologique_final4.pdf
2021
Canada
drug information
albumin/globulin ratio
What Month is it
Ratio
durvalumab
Strategy
Regulatory Report
durvalumab
research report
Durvalumab
---
https://pgtmsite.files.wordpress.com/2024/01/mic_-durvalumab_ce-1.pdf
2021
false
false
false
Canada
evaluation of the transparency committee
body weight
methyl isocyanate
durvalumab
durvalumab
Imfinzi
microbial sensitivity tests
hospitals, proprietary
---
https://www.has-sante.fr/jcms/p_3242177/fr/imfinzi-cancer-bronchique-a-petites-cellules-a-un-stade-etendu-cbpc-se
2021
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
treatment outcome
durvalumab
antineoplastic agents
infusions, intravenous
small cell lung carcinoma
bronchial neoplasms
antineoplastic combined chemotherapy protocols
Carboplatin/Durvalumab/Etoposide Regimen
Cisplatin/Durvalumab/Etoposide Regimen
cisplatin
etoposide
carboplatin
adult
Extensive Stage Lung Small Cell Carcinoma
B7-H1 Antigen
durvalumab
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3239200/fr/imfinzi
2021
false
false
false
France
durvalumab
carcinoma, non-small-cell lung
bronchial neoplasms
adult
infusions, intravenous
antineoplastic agents
continuity of patient care
drug monitoring
guidelines for drug use
treatment outcome
insurance, health, reimbursement
survival analysis
durvalumab
antineoplastic agents
evaluation of the transparency committee
durvalumab
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2908478/fr/imfinzi
https://www.has-sante.fr/portail/jcms/c_2908478/fr/imfinzi-durvalumab-anticorps-monoclonal
2019
false
true
false
false
France
infusions, intravenous
carcinoma, non-small-cell lung
durvalumab
adult
antineoplastic agents
treatment outcome
CD274 protein, human
guidelines for drug use
evaluation of the transparency committee
durvalumab
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
durvalumab
durvalumab
durvalumab
carcinoma, non-small-cell lung
adult
aged
B7-H1 Antigen
infusions, intravenous
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
bronchial neoplasms
antibodies, monoclonal
antibodies, monoclonal
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00384
2016
false
true
false
Canada
French
drug information
durvalumab
antibodies, monoclonal
---
